Table 6.

Current and future trials of targeted therapy for refractory and/or recurrent Ewing's sarcoma (EWS).

Sponsor site	Drugs	Rationale	Comments	PI contact info/clinicaltrials.gov identifier
Imclone/UTMDACC, Wayne State	IMCA12 + temsirolimus	IGF1R + mTOR	Recently completed accrual for expanded EWS cohort at temsirolimus dose higher than that in children	Aung Naing, MD anaing@mdanderson.org NCT00678769
COG	IMCA12 + temsirolimus	IGF1R + mTOR	Phase I study;pediatric patients with recurrent or refractory solid tumors	Maryam Fouladi, MD maryam.fouladi@cchmc.org ADVL0813; NCT00880282
MSKCC/CTEP	IMCA12 + temsirolimus	IGF1R + mTOR	Phase II study in recurrent or refractory soft tissue or bone sarcomas	Robert Maki, MD PhD makir@mskcc.org NCT01016015

PI: principal investigator; UTMDACC: The University of Texas MD Anderson Cancer Center; IGF1R: insulin-like growth factor 1 receptor; mTOR: mammalian target of rapamycin; COG: Children's Oncology Group; MSKCC: Memorial Sloan Kettering Cancer Center; CTEP: Cancer Therapy Evaluation Program.